U.S. Topical Pain Relief Market is Estimated to Value Over USD 3.4 Billion by 2026 End

  • 16 Sep 2019

U.S. Topical Pain Relief Market is estimated to value over USD 3.4 billion by 2026 end and register a CAGR of over 5% during the forecast period 2019 to 2026.

 

The U.S. topical pain relief market growth is primarily steered by an increase in the prevalence of diabetic neuropathy, arthritis and other orthopaedic conditions, leading to pain. Other factors boosting the market growth are an increase in topical pain relief product adoption owing to a reduction in side effects in comparison with oral pain relief, an increase in demand for topical pain relief by athletes and a soaring geriatric population across the United States. 

 

Although, factors like topical pain relief medications have a strong and unpleasant smell and can cause irritation of the skin that can impede the U.S. topical pain relief market growth. On the contrary, the development of an online platform for topical therapeutics is projected to provide profitable opportunities for market growth.

 

Non-Opioids is Projected to be a Lucrative Segment Over the Forecast Period

The U.S. topical pain relief market is segmented based on therapeutic class, formulation, distribution channel and type. Based on therapeutic class, the market is bifurcated into non-opioids and opioids. The non-opioids segment is further divided into methyl salicylate, capsaicin, lidocaine, nonsteroidal anti-inflammatory drugs (NSAIDs), and other non-opioids. The opioids segment is further fragmented into fentanyl and buprenorphine. The non-opioids segment had the largest U.S. topical pain relief market share in 2017 and is predicted to showcase this trend over the forecast period due to easy availability and high preferability of non-opioids drugs.

 

By type, the U.S. topical pain relief market is fragmented into and over-the-counter (OTC) relief and prescription pain relief. Over-the-counter pain relief segment gauged the largest U.S. topical pain relief market share in 2017 owing to high demand for topical pain relief products by athletes and its easy availability. Depending on the type of formulation, the market is classified into gel, cream, patch, spray and others. Cream-based pain relief segment gauged the largest market share in 2017 owing to high product availability coupled with lesser side effects and high success rate. On the contrary, patch pain relief segment is predicted to grow at a high CAGR over the forecast period.

 

The key players of this market include Johnson & Johnson, Novartis AG, GlaxoSmithKline Plc., Pfizer Inc., Reckitt Benckiser Group Plc., Sanofi S.A., Topical BioMedics, Inc., AdvaCare Pharma, Sun Pharmaceutical Industries Ltd., and Nestle S.A.

 

U.S Topical Pain Relief Market Segmentation:

 By Therapeutic Class

  • Non-opioids 
    • Non-steroidal Anti-Inflammatory Drugs (NSAIDS)
    • Methyl Salicylate
    • Capsaicin
    • Lidocaine
    • Other Non-opioids
  • Opioids 

By Type

  • Prescription Pain Relief
  • Over-the-counter (OTC) Pain Relief

By Formulation

  • Cream
  • Gel
  • Spray
  • Patch
  • Others

By Distribution Channel

  • Pharmacies & Drug Stores
  • E-commerce
  • Retail & Grocery Stores

 

FutureWise Key Takeaways:

• Growth prospects

• SWOT analysis 

• Key trends 

• Key data-points affecting market growth 

 

Objectives of the Study:

  • To provide with an exhaustive analysis on the U.S topical pain relief market by therapeutic class, by type, by formulation and by distribution channel 
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market 
  • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • Profiling of companies to evaluate their market shares, strategies, financials and core competencies

 

Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com